Clinical trials: sponsored by Eli Lilly and Company
Healthy, Type 2 Diabetes Mellitus (T2D)
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants.
- Trial name
- NCT06869018
- Testing
- LY3549492
- Where
- 4 sites in Japan
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3985863 in Healthy Participants
The purpose of this study is to evaluate how well LY3985863 is tolerated and what side effects may occur in healthy Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin).
- Trial name
- NCT07030127
- Testing
- LY3985863
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Cancer
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
The main purpose of this study is to explore the safety and any side effects of LY4066708 in healthy participants. The study will also measure how much LY4066708 gets into the bloodstream and the central nervous system and how…
- Trial name
- NCT07046559
- Testing
- LY4066708
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Remternetug (LY3372993) in Healthy Participants
The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS).
- Trial name
- NCT07056309
- Testing
- Remternetug (Test), Remternetug (Reference)
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Olomorasib (LY3537982) in Healthy Japanese Participants
The purpose of this study is to compare and see how food affects the amount of olomorasib in the blood when olomorasib is taken in two different capsule forms. Participation in the study will last approximately 6 weeks.
- Trial name
- NCT07124013
- Testing
- Olomorasib
- Where
- Japan
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY4064809 in Healthy Adult Chinese Participants
The main purpose of this study is to measure how much LY4064809 gets into the bloodstream and how long it takes the body to eliminate it in healthy participants. It also looks at safety and tolerability in healthy participants.
- Trial name
- NCT07247357
- Testing
- LY4064809
- Where
- Singapore
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to…
- Trial name
- NCT06475729
- Testing
- Citrate-Free Mirikizumab
- Where
- 6 sites in United States
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin.
- Trial name
- NCT05444556
- Testing
- Imlunestrant, Repaglinide, Omeprazole
- Where
- 3 sites in United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3484356 in Healthy Female Participants
The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food.
- Trial name
- NCT04840888
- Testing
- LY3484356, Omeprazole, Itraconazole
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants.
- Trial name
- NCT05469113
- Testing
- Repaglinide, Selpercatinib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of [¹⁴C]-LY3484356 in Healthy Female Participants
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study has two parts.
- Trial name
- NCT04991766
- Testing
- [¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatic Insufficiency, Healthy
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female…
- Trial name
- NCT05440344
- Testing
- Imlunestrant
- Where
- 3 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Imlunestrant (LY3484356) in Healthy Women
The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when administered orally on the levels of midazolam in the blood stream in healthy women of non-childbearing potential.
- Trial name
- NCT05509816
- Testing
- Midazolam, Imlunestrant
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3463251 in Healthy Participants
The purpose of this study is to evaluate the safety and tolerability (side effects) of single (Part A) and multiple (Part B) doses of the study drug when it is administered subcutaneously (under the skin) into the abdomen.
- Trial name
- NCT03764774
- Testing
- LY3463251
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3522348 in Healthy Participants
The main purpose of this study in healthy participants is to learn more about the safety of LY3522348 and any side effects that might be associated with it.
- Trial name
- NCT04559568
- Testing
- LY3522348, Midazolam
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
The main purpose of this study is to assess the effect of selpercatinib on how fast midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants.
- Trial name
- NCT05338476
- Testing
- Midazolam, Selpercatinib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide.
- Trial name
- NCT06890611
- Testing
- Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3526318 in Healthy Women
The main purpose of this study is to learn more about how LY3526318 affects blood flow to the skin in healthy women. For each participant, the study will last up to 28 days and Part B will last up to 78 days, including screening…
- Trial name
- NCT04183283
- Testing
- LY3526318
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Atopic Dermatitis
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants.
- Trial name
- NCT06119529
- Testing
- LY3872386, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants
The aim of this study is to evaluate the safety, tolerability and PK of LY3876602 after administering it as single ascending doses and, following a data review, proceeding to multiple ascending doses in healthy participants.
- Trial name
- NCT06007638
- Testing
- LY3876602
- Where
- Netherlands
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company